Motor function optimization in advanced Parkinson*s disease patients, combined with galantamine to prevent visual hallucinations.

Phase 4

Completed

• Conditions: Parkinson`s disease; visual hallucinations; 10028037; 10013511

• Registration Number: NL-OMON32454
• Lead Sponsor: niversitair Medisch Centrum Groningen

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 10

Inclusion Criteria

- PD according to the UK Brain Bank Criteria
- At least weakly visual hallucinations
- Patients must be able to understand the procedures
- Stable medication for at least 1 month

Exclusion Criteria

- Unstable internal disease
- Major depression
- Use of anticholinergics, amantadine or selegiline (washout at least 2 weeks)
- Tricyclic antidepressants (washout al least 1 month)
- Use of cholinesterase inhibitors

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Cognition and existence of neuropsychiatric symptoms, for which the following<br /><br>tests will be used: -University of Miami Parkinson*s disease Hallucinations<br /><br>Questionnaire (UM-PDHQ).</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>- SCales for Outcome of PArkinson`s disease (SCOPA) - part cognition<br /><br>(SCOPA-Cog), this is a questionnaire focussing on executive, visuospatial and<br /><br>(working)memory functions.<br /><br>- Motorfunction: Unified Parkinson`s Disease Rating Scale (UPDRS) - part 3<br /><br>(motorfunction).<br /><br>- Mood: BDI (questionnaire depressive complaints)<br /><br>- Adverse events</p><br>